Live feed07:00:00·1hPRReleasevia QuantisnowTvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target EngagementByQuantisnow·Wall Street's wire, on your screen.TVRD· Tvardi Therapeutics Inc.Health Care
